摘要 |
<p num="1"><br/><br/><br/>The present application discloses a compound, or enantiomers, stereoisomers, <br/>rotamers, tautomers, racemates or prodrug of said compound, or <br/>pharmaceutically acceptable salts, solvates or esters of said compound, or of <br/>said prodrug, said compound having the general structure shown in Formula 1: <br/>Chemical formual should be inserted here as it appears on the abstract in <br/>paper form. and the pharmaceutically acceptable salts, solvates and esters <br/>thereof. Also disclosed is a method of treating chemokine mediated diseases, <br/>such as, palliative therapy, curative therapy, prophylactic therapy of certain <br/>diseases and conditions such as inflammatory diseases (non limiting example(s) <br/>include, psoriasis), autoimmune diseases (non limiting example(s) include, <br/>rheumatoid arthritis, multiple sclerosis), graft rejection (non limiting <br/>example(s) include, allograft rejection, xenograft rejection), infectious <br/>diseases (e.g , tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-<br/>type hypersensitivity responses, ophthalmic inflammation, type I diabetes, <br/>viral meningitis and tumors using a compound of Formula 1.<br/>
|
申请人 |
SCHERING CORPORATION;PHARMACOPEIA, INC. |
发明人 |
WONG, MICHAEL K. C.;SHU, YOUHENG;YU, WENSHENG;ROSENBLUM, STUART B.;KOZLOWSKI, JOSEPH A.;MCGUINNESS, BRIAN F.;SHAO, YUEFEI;HOBBS, DOUGLAS W. |